Increased YKL-40 levels are linked with disease severity of initially diagnosed Graves’ disease

References

• Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American thyroid association and American association of clinical endocrinologists. Thyroid: Offic J Am Thyroid Association. 2011;21:593–7.
   PubMed Web of Science ®Google Scholar
• Farling PA. Thyroid disease. Br J Anaesth. 2000;85:15–28.
   PubMed Web of Science ®Google Scholar
• Subekti I, Pramono LA. Current diagnosis and management of Graves’ disease. Acta Med Indones. 2018;50:177–182.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Elia G, et al. Graves’ disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101388.
   PubMed Web of Science ®Google Scholar
• Siomkajło M, Dybko J, Daroszewski J. Regulatory lymphocytes in thyroid orbitopathy and autoimmune thyroid diseases. Postepy Hig Med Dosw (Online). 2016;70:1378–1388.
   PubMedGoogle Scholar
• Lee CG, Da Silva CA. Dela Cruz CS, et al.Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479–501.
   PubMed Web of Science ®Google Scholar
• PV H, KG M, Price P, et al. Report of the Ad Hoc committee on nomenclature and standards for bone proteins and growth factors. J Bone Miner Res. 1986;1:485–486.
   PubMed Web of Science ®Google Scholar
• El-Fattah AA A, Sadik NAH, Shaker OG, et al. Single nucleotide polymorphism in SMAD7 and CHI3L1 and colorectal cancer risk. Mediators Inflamm. 2018;2018:9853192.
   PubMed Web of Science ®Google Scholar
• Long X, He X, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J. 2017;49:1501924.
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, Palermo G, et al. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16:593–600.
   PubMed Web of Science ®Google Scholar
• Tong X, Wang D, Liu S, et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:409–418.
   PubMed Web of Science ®Google Scholar
• CN R, Vestergaard H YKL-40–an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61.
   Google Scholar
• Väänänen T, Vuolteenaho K, Kautiainen H, et al. Glycoprotein YKL-40: a potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDmards and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS ONE. 2017;12:e0183294.
   PubMed Web of Science ®Google Scholar
• Huang R, Yao J, Ding X, et al. Plasma YKL-40: a potential biomarker for tumor invasion in esophageal cancer. Clin Lab. 2020;66(3).
   Web of Science ®Google Scholar
• Roslind A, Palle C, Johansen JS, et al. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scand J Clin Lab Invest. 2020;80:687–693.
   PubMed Web of Science ®Google Scholar
• Yasar O, Akcay T, Obek C, et al. Diagnostic potential of YKL-40 in bladder cancer. Urol Oncol. 2016;34: 257. e19-24.
   PubMed Web of Science ®Google Scholar
• Wan G, Xiang L, Sun X, et al. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget. 2017;8:5382–5391.
   PubMedGoogle Scholar
• Cheng SP, Lee JJ, Chang YC, et al. Overexpression of chitinase-3-like protein 1 is associated with structural recurrence in patients with differentiated thyroid cancer. J Pathol. 2020;252:114–124.
   PubMed Web of Science ®Google Scholar
• Luo D, Chen H, Lu P, et al. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark. 2017;18:273–284.
   PubMed Web of Science ®Google Scholar
• He K, Jiang P, Liu BL, et al. Intrathyroid injection of dexamethasone inhibits Th2 cells in Graves’ disease. Arch Endocrinol Metab. 2020;64(3):243–250.
   PubMed Web of Science ®Google Scholar
• Harvey S, Weisman M, O’Dell J, et al. Chondrex: new marker of joint disease. Clin Chem. 1998 Mar 1;44(3):509–516.
   PubMed Web of Science ®Google Scholar
• Pawlowski P, Reszec J, Eckstein A, et al. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical implications. Mediators Inflamm. 2014;2014:412158.
   PubMed Web of Science ®Google Scholar
• Kwak EJ, Hong JY, Kim MN, et al. Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation. Clin Exp Allergy. 2019;49(11):1464–1474.
   PubMed Web of Science ®Google Scholar
• Tizaoui K, Yang JW, Lee KH, et al. The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review. Int J Biol Sci. 2022;18(9):3731–3746.
   PubMed Web of Science ®Google Scholar
• Pérez C, Scrimshaw NS, Muñoz JA. Técnicas de las encuestas sobre bocio endémico. En: El bocio endémico. In: Monografía de la OMS. Vol. 44. Ginebra: WHO; 1961. pp. 399–414.
   Google Scholar
• Specjalski K, Chełmińska M, Jassem E. YKL-40 protein correlates with the phenotype of asthma. Lung. 2015;193:189–194.
   PubMed Web of Science ®Google Scholar
• Gao MZ, Wei YY, Xu QW, et al. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem. 2019;56:95–99.
   PubMed Web of Science ®Google Scholar
• Prakash M, Bodas M, Prakash D, et al. Diverse pathological implications of YKL-40: answers may lie in ‘outside-in’ signaling. Cell Signal. 2013;25:1567–1573.
   PubMed Web of Science ®Google Scholar
• Kjaergaard AD, Johansen JS, Bojesen SE, et al. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit Rev Clin Lab Sci. 2016;53:396–408.
   PubMed Web of Science ®Google Scholar